MaxCyte IncNASDAQ:MXCT
- LAST PRICE3.7600
- TODAY'S CHANGE (%)0.0400 (1.0753%)
- Bid / Lots3.7500/ 16
- Ask / Lots4.3700/ 1
- Open / Previous Close3.7400 / 3.7200
- Day Range
- 52 Week Range
- Volume360,221
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MXCT |
|---|---|---|
| 09:32 ET | 8011 | 3.67 |
| 09:34 ET | 2577 | 3.675 |
| 09:36 ET | 3890 | 3.66 |
| 09:38 ET | 761 | 3.67 |
| 09:39 ET | 100 | 3.7 |
| 09:43 ET | 4716 | 3.7223 |
| 09:45 ET | 3151 | 3.71 |
| 09:48 ET | 1390 | 3.7 |
| 09:50 ET | 480 | 3.7 |
| 09:52 ET | 4273 | 3.715 |
| 09:56 ET | 240 | 3.71 |
| 09:57 ET | 120 | 3.71 |
| 09:59 ET | 1370 | 3.7 |
| 10:01 ET | 2020 | 3.71 |
| 10:03 ET | 200 | 3.71 |
| 10:06 ET | 3921 | 3.69 |
| 10:08 ET | 9465 | 3.705 |
| 10:10 ET | 400 | 3.7 |
| 10:12 ET | 891 | 3.705 |
| 10:14 ET | 323 | 3.705 |
| 10:17 ET | 1940 | 3.715 |
| 10:19 ET | 1100 | 3.71 |
| 10:21 ET | 300 | 3.715 |
| 10:24 ET | 6290 | 3.745 |
| 10:26 ET | 700 | 3.735 |
| 10:28 ET | 1200 | 3.745 |
| 10:30 ET | 400 | 3.74 |
| 10:32 ET | 2358 | 3.74 |
| 10:33 ET | 600 | 3.745 |
| 10:35 ET | 1300 | 3.755 |
| 10:37 ET | 2018 | 3.745 |
| 10:39 ET | 800 | 3.745 |
| 10:42 ET | 700 | 3.74 |
| 10:44 ET | 500 | 3.725 |
| 10:46 ET | 1100 | 3.725 |
| 10:48 ET | 500 | 3.73 |
| 10:50 ET | 1204 | 3.72 |
| 10:51 ET | 900 | 3.715 |
| 10:53 ET | 900 | 3.705 |
| 10:55 ET | 500 | 3.705 |
| 10:57 ET | 785 | 3.695 |
| 11:00 ET | 1100 | 3.69 |
| 11:02 ET | 700 | 3.69 |
| 11:04 ET | 678 | 3.6877 |
| 11:06 ET | 500 | 3.69 |
| 11:08 ET | 1306 | 3.695 |
| 11:09 ET | 800 | 3.695 |
| 11:11 ET | 800 | 3.7 |
| 11:13 ET | 5513 | 3.68 |
| 11:15 ET | 1348 | 3.68 |
| 11:18 ET | 882 | 3.6701 |
| 11:20 ET | 300 | 3.68 |
| 11:22 ET | 950 | 3.675 |
| 11:24 ET | 4072 | 3.67 |
| 11:26 ET | 2800 | 3.665 |
| 11:27 ET | 2131 | 3.685 |
| 11:31 ET | 100 | 3.685 |
| 11:33 ET | 1303 | 3.675 |
| 11:36 ET | 500 | 3.675 |
| 11:38 ET | 606 | 3.675 |
| 11:40 ET | 5615 | 3.685 |
| 11:42 ET | 400 | 3.685 |
| 11:44 ET | 913 | 3.695 |
| 11:45 ET | 100 | 3.7 |
| 11:47 ET | 312 | 3.695 |
| 11:49 ET | 300 | 3.7 |
| 11:51 ET | 975 | 3.695 |
| 11:54 ET | 512 | 3.7 |
| 11:56 ET | 2308 | 3.695 |
| 11:58 ET | 942 | 3.695 |
| 12:00 ET | 200 | 3.7 |
| 12:02 ET | 1113 | 3.695 |
| 12:03 ET | 975 | 3.695 |
| 12:05 ET | 827 | 3.695 |
| 12:07 ET | 2062 | 3.695 |
| 12:09 ET | 500 | 3.695 |
| 12:12 ET | 400 | 3.7 |
| 12:14 ET | 981 | 3.695 |
| 12:16 ET | 500 | 3.695 |
| 12:18 ET | 2633 | 3.685 |
| 12:20 ET | 1100 | 3.685 |
| 12:21 ET | 13913 | 3.705 |
| 12:23 ET | 5403 | 3.705 |
| 12:25 ET | 1100 | 3.705 |
| 12:27 ET | 3956 | 3.705 |
| 12:30 ET | 3850 | 3.705 |
| 12:32 ET | 900 | 3.705 |
| 12:34 ET | 33891 | 3.7 |
| 12:36 ET | 5602 | 3.705 |
| 12:38 ET | 1778 | 3.705 |
| 12:39 ET | 830 | 3.705 |
| 12:41 ET | 8130 | 3.715 |
| 12:43 ET | 18810 | 3.715 |
| 12:45 ET | 4726 | 3.734 |
| 12:48 ET | 2475 | 3.735 |
| 12:50 ET | 2671 | 3.745 |
| 12:52 ET | 1599 | 3.76 |
| 12:54 ET | 5435 | 3.78 |
| 12:56 ET | 3171 | 3.775 |
| 12:57 ET | 3747 | 3.77 |
| 12:59 ET | 60292 | 3.76 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MaxCyte Inc | 393.1M | -10.6x | --- |
Nano-X Imaging Ltd | 408.0M | -6.6x | --- |
908 Devices Inc. | 168.3M | -4.6x | --- |
Electromed Inc | 126.5M | 29.6x | +10.79% |
Olympus Corp | 18.7B | 113.4x | --- |
Neuropace Inc | 208.3M | -6.1x | --- |
Company Information
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Contact Information
- Headquarters
- 9713 KEY WEST AVENUE,, SUITE 400ROCKVILLE, MD, United States 20850
- Phone
- 301-517-5556
- Fax
- 301-944-1703
Executives
- Non-Executive Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Maher Masoud
- Chief Financial Officer
- Douglas Swirsky
- Executive Vice President - Global Sales
- Thomas Ross
- Senior Vice President, General Counsel, Corporate Secretary
- David Sandoval
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $393.1M |
|---|---|
Revenue (TTM) | $44.1M |
Shares Outstanding | 104.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.35 |
Book Value | $2.23 |
P/E Ratio | -10.6x |
Price/Sales (TTM) | 8.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -107.59% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
